Ovid Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-26.8%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$0.44next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Update | 12 Nov 2026 |
| Q4 2026 and Full Year 2026 Financial Results | 18 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly165.6MTarget: Sufficient to fund operations into 2029
OV329 Clinical Development Progress QuarterlyTarget: Initiation of Phase 2 trial in focal onset seizures (FOS) and Phase 2a proof-of-concept in tuberous sclerosis complex (TSC) seizures
OV4071 Phase 1 Clinical Progress QuarterlyTarget: Completion of Phase 1 healthy volunteer dosing and initiation of ketamine challenge study in H2 2026
Watch Items
- OV329 Phase 2 Trial InitiationTrigger: Regulatory clearance and first patient dosed in FOS Phase 2 studyAction: Monitor clinical trial registry updates and company press releases for study start confirmation.
- OV4071 Ketamine Challenge Study ResultsTrigger: Open-label photo paroxysmal response (PPR) initiation and results in H2 2026Action: Evaluate electrophysiology and biomarker data to confirm direct KCC2 activation in humans.
- Cash Burn Rate and RunwayTrigger: Quarterly operating expenses exceeding $20 millionAction: Re-assess cash runway projections and evaluate potential need for additional non-dilutive or dilutive financing.
Research as of 19 Jun 2026